Abstract 55P
Background
To compare the toxicity profiles of contemporary stereotactic radiosurgery (SRS), fractionated radiotherapy (FRT) with modern techniques, or transsphenoidal surgery on nonfunctioning pituitary macroadenoma.
Methods
We enrolled patients with nonfunctioning pituitary macroadenoma and categorized them into three groups according to treatment modality to compare treatment outcomes: group 1, those receiving modern FRT; group 2, those receiving contemporary SRS; and group 3, that receiving transsphenoidal surgery.
Results
248 patients in total with nonfunctioning pituitary macroadenoma were selected in our study. In multivariable Cox proportional hazards regression analysis, adjusted HRs (aHRs; 95% confidence interval [CI]) of local recurrence were derived for the SRS and transsphenoidal surgery cohorts compared with the FRT cohort was no significant difference in secondary primary brain or head and neck cancers, hypopituitarism, and optic nerve injury between three treatment cohorts. In multivariable Cox proportional hazards regression analysis, adjusted HRs (aHRs; 95% confidence interval [CI]) of stroke risk were derived for the SRS and transsphenoidal surgery cohorts compared with the FRT cohort were 0.37 (0.14-0.99) and 0.51 (0.31-0.84), respectively.
Conclusions
Contemporary SRS and transsphenoidal surgery in treatment of nonfunctioning pituitary macroadenoma would bring in equal toxicity profiles. Modern FRT might increase risk of stroke in treatment of nonfunctioning pituitary macroadenoma significantly.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
185P - Evaluation of the effect of cholesorption on the concentration of TNF-α in the serum of the blood in tumours of the biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
186P - Efficacy and safety of sorafenib following hepatic resection in patients with hepatocellular carcinoma: A meta-analysis
Presenter: Yang Yuan
Session: Poster display session
Resources:
Abstract
187P - Correlation between spleenic dose and grade of hematological toxicity in chemoradiation of stomach
Presenter: Umesh Velu
Session: Poster display session
Resources:
Abstract
188P - Survival and prognostic factors in cholangiocarcinoma: A single-center experience
Presenter: Sonngwit Payapwattanawong
Session: Poster display session
Resources:
Abstract
189P - Stereotactic body radiotherapy in primary hepatocellular carcinoma and oligometastatis to liver: A single Institution experience
Presenter: Sayan Paul
Session: Poster display session
Resources:
Abstract
190P - Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
Presenter: Yusuke Nagata
Session: Poster display session
Resources:
Abstract
191P - Assessment of efficacy and safety of sorafenib versus no treatment in Egyptian hepatocellular carcinoma patients
Presenter: Noha El Baghdady
Session: Poster display session
Resources:
Abstract
192P - Clinical importance of the determination of interleukin-6 in bile and blood in tumours of biliopancreatoduodenal zone
Presenter: Marufjon Salokhiddinov
Session: Poster display session
Resources:
Abstract
193P - Metastatic carcinoma gall bladder: A clinicoepidemiological profile of Indian patients
Presenter: Anvesh Rathore
Session: Poster display session
Resources:
Abstract
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract